Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution
Endo International plc (NASDAQ: ENDP) announced that Par Pharmaceutical has started shipping the first generic version of Merz's CUVPOSA® (glycopyrrolate) 1 mg/5 mL oral solution in the U.S. after receiving FDA approval for its Abbreviated New Drug Application. CUVPOSA® sales were approximately $27 million for the year ending October 31, 2021. Jon Holden, Endo's Senior VP, emphasized the importance of providing families with a generic option, enhancing the company's portfolio of cost-effective treatments.
- Launch of the first generic version of CUVPOSA, expanding product offerings and market presence.
- Estimated market size of CUVPOSA sales at approximately $27 million, indicating potential revenue growth.
- None.
DUBLIN, Jan. 4, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic version of Merz's CUVPOSA® (glycopyrrolate) 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
"We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo. "Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic products—and our reputation for dependable quality is an especially essential factor when treating children."
According to IQVIA™, CUVPOSA® sales were approximately
CUVPOSA® is a registered trademark of Merz Pharmaceuticals, LLC.
About Endo
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.
About Par Pharmaceutical
Par Pharmaceutical develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses an expanding portfolio that includes sterile injectables, alternative dosage forms and other differentiated products. Par Pharmaceutical is an Endo company. Learn more at www.parpharm.com.
Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Mr. Holden and any statements relating to product launch, shipments, sales potential, quality, safety or cost. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this press release reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this press release. Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: the outcome of our strategic review, contingency planning and any potential restructuring; the timing, impact or results of any pending or future litigation, investigations or claims or actual or contingent liabilities, settlement discussions, negotiations or other adverse proceedings; our ability to satisfy judgments or settlements or pursue appeals including bonding requirements; our ability to adjust to changing market conditions; our ability to attract and retain key personnel; our inability to maintain compliance with financial covenants and operating obligations which would expose us to potential events of default under our outstanding indebtedness; our ability to incur additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or general corporate or other purposes; our ability to refinance our indebtedness; a significant reduction in our short-term or long-term revenues which could cause us to be unable to fund our operations and liquidity needs or repay indebtedness. The occurrence or possibility of any such result has caused us to engage, and may result in further engagement in strategic reviews that ultimately may result in our pursuing one or more significant corporate transactions or other remedial measures, including on a preventative or proactive basis. Those remedial measures could include a potential corporate reorganization, restructuring or bankruptcy filing involving all or a portion of our business, asset sales or other divestitures, cost-saving initiatives, corporate realignments or strategic partnerships. Some of these measures could take significant time to implement and others may require judicial or other third-party approval. Any such actions may be complex, could entail significant costs and charges or could otherwise negatively impact shareholder value, and there can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to us, or at all, or that they will result in their intended benefits. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission.
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-launches-first-generic-version-of-cuvposa-glycopyrrolate-oral-solution-301454073.html
SOURCE Endo International plc
FAQ
What did Endo International announce on January 4, 2022?
What is the significance of the FDA approval for Endo's product?
Who is the Senior VP of Endo that commented on the product launch?
What is the sales potential of CUVPOSA according to the latest data?
How does the generic version of CUVPOSA impact families?
